Background: The clinical significance of urinary liver fatty acid-binding protein (u-LFABP) in acute heart failure (AHF) patients remains unclear. Methods and Results: The u-LFABP levels on admission of 293 AHF patients were analyzed. The patients were divided into 2 groups according to the u-LFABP quartiles (Q1, Q2, and Q3 = low u-LFABP [L] group vs. Q4 = high u-LFABP [H] group). We evaluated the diagnostic and prognostic value of u-LFABP and compared the findings between the chronic kidney disease (CKD; n = 165) and non-CKD patients (n = 128). Acute kidney injury (AKI) during the first 7 days was evaluated based on the RIFLE criteria. In the non-CKD group, the number of AKI patients during the first 7 days was significantly greater in the H group (70.0%) than in the L group (45.6%). A multivariate logistic regression model indicated that the H group (odds ratio: 3.850, 95% confidence interval [CI] 1.128-13.140) was independently associated with AKI during the first 7 days. The sensitivity and specificity of u-LFABP for predicting AKI were 63.6 and 59.7% (area under the ROC curve 0.631) at 41.9 ng/mg × cre. A Cox regression model identified the H group (hazard ratio: 13.494, 95% CI 1.512-120.415) as an independent predictor of the 60-day mortality. A Kaplan-Meier curve, including all-cause death within 60 days, showed a significantly poorer survival rate in the H group than in the L group (p = 0.036). Conclusions: The u-LFABP level is an effective biomarker for predicting AKI during the first 7 days of hospitalization and an adverse outcome in AHF patients with non-CKD.

Keywords:
Acute decompensated heart failure, Acute kidney injury, Worsening renal function, Liver fatty acid-binding protein, Neutrophil gelatinase-associated lipocalin, Mortality
1.
Ronco C, Di Lullo L: Cardiorenal syndrome. Heart Fail Clin 2014;10:251-280.
2.
Hata N, Yokoyama S, Shinada T, et al: Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur J Heart Fail 2010;12:32-37.
3.
Shirakabe A, Hata N, Kobayashi N, et al: Long-term prognostic impact after acute kidney injury in patients with acute heart failure: evaluation of the RIFLE criteria. Int Heart J 2012;53:313-319.
4.
Shirakabe A, Hata N, Kobayashi N, et al: Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J 2013;77:687-696.
5.
Maisel AS, Mueller C, Fitzgerald R, et al: Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011;13:846-851.
6.
Collins SP, Hart KW, Lindsell CJ, et al: Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail 2012;14:1020-1029.
7.
Matsui K, Kamijo-Ikemori A, Sugaya T, et al: Usefulness of urinary biomarkers in early detection of acute kidney injury after cardiac surgery in adults. Circ J 2012;76:213-220.
8.
Manabe K, Kamihata H, Motohiro M, et al: Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury. Eur J Clin Invest 2012;42:557-563.
9.
Shirakabe A, Hata N, Kobayashi N, et al: Serum heart-type fatty acid-binding protein level can be used to detect acute kidney injury on admission and predict an adverse outcome in patients with acute heart failure. Circ J 2015;79:119-128.
10.
Mullens W, Abrahams Z, Francis GS, et al: Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-596.
11.
Gheorghiade M, Zannad F, Sopko G, et al: Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-3968.
12.
McMurray JJ, Adamopoulos S, Anker SD, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
13.
Bellomo R, Ronco C, Kellum JA, et al: Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs - the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212.
14.
Mathew TH, Johnson DW, Jones GR: Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Med J Aust 2007;187:459-463.
15.
Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
16.
Iseki K: Chronic kidney disease in Japan. Intern Med 2008;47:681-689.
17.
Maatman RG, van de Westerlo EM, van Kuppevelt TH, et al: Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288:285-290.
18.
Noiri E, Doi K, Negishi K, et al: Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol 2009;296:F669-F679.
19.
Kamijo A, Kimura K, Sugaya T, et al: Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23-30.
20.
Star R, Hostetter T, Hortin GL: New markers for kidney disease. Clin Chem 2002;48:1375-1376.
21.
Kamijo A, Kimura K, Sugaya T, et al: Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002;62:1628-1637.
22.
Yokoyama T, Kamijo-Ikemori A, Sugaya T, et al: Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 2009;174:2096-2106.
23.
Veerkamp JH, Peeters RA, Maatman RG: Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biohys Acta 1991;1081:1-24.
24.
Doi K, Negishi K, Ishizu T, et al: Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med 2011;39:2464-2469.
25.
Matsui K, Kamijo-Ikemorif A, Sugaya T, et al: Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am J Pathol 2011;178:1021-1032.
26.
Ferguson MA, Vaidya VS, Waikar SS, et al: Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int 2010;77:708-714.
27.
Kamijo-Ikemori A, Sugaya T, Yasuda T, et al: Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011;34:691-696.
28.
Kamijo-Ikemori A, Sugaya T, Kimura K: Urinary fatty acid binding protein in renal disease. Clin Chim Acta 2006;374:1-7.
29.
Shrestha K, Shao Z, Singh D, et al: Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol 2012;110:1329-1335.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.